| Followers | 4045 |
| Posts | 152978 |
| Boards Moderated | 3 |
| Alias Born | 08/05/2009 |
Wednesday, December 21, 2022 9:42:51 AM
Starting to make a new tun
lol
lol
Recent SMMT News
- B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic • PR Newswire (US) • 05/18/2026 06:22:00 PM
- B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic • PR Newswire (Canada) • 05/18/2026 06:22:00 PM
- A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology • GlobeNewswire Inc. • 05/14/2026 01:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/30/2026 09:00:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:40:49 PM
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 • Business Wire • 04/30/2026 08:32:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/17/2026 09:00:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/17/2026 08:12:22 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/06/2026 08:28:53 PM
- Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 • Business Wire • 03/27/2026 12:15:00 PM
- Summit Therapeutics to Present at Upcoming Investor Conferences • Business Wire • 02/26/2026 11:45:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/23/2026 09:58:58 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/23/2026 09:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:07:53 PM
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 • Business Wire • 02/23/2026 09:05:00 PM
- Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 • Business Wire • 02/17/2026 10:05:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/30/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 12:35:03 PM
- Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy • Business Wire • 01/29/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2026 09:01:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 12:43:04 PM
- Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) • Business Wire • 01/12/2026 11:15:00 AM
- Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC • Business Wire • 01/12/2026 11:00:00 AM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/10/2026 01:16:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 11:52:50 PM

